This is an old revision of this page, as edited by Mo18ekula (talk | contribs) at 15:13, 17 December 2024 (←Created page with '{{Infobox drug | drug_name = Dazadrol | image = Dazadrol.svg | width = 250px | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = | class = | ATC_prefix = | ATC_suffix = <!-- Legal status --> | legal_status = <!-- Pharmaco...'). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:13, 17 December 2024 by Mo18ekula (talk | contribs) (←Created page with '{{Infobox drug | drug_name = Dazadrol | image = Dazadrol.svg | width = 250px | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = | class = | ATC_prefix = | ATC_suffix = <!-- Legal status --> | legal_status = <!-- Pharmaco...')(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Clinical data | |
---|---|
Other names | Sch 12650 |
Identifiers | |
IUPAC name
| |
CAS Number |
|
ChemSpider | |
Chemical and physical data | |
Formula | C15H14ClN3O |
Molar mass | 287.75 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Antidepressant.
Noradrenaline reuptake inhibitor and gastric acid secretion inhibitor.
Synthesis
Patent (Ex 12): #3 substance:
The reaction between p-chlorophenylacetonitrile (1) and 2-bromopyridine (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving PC20361737 (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated, multiply benzylic carbon. There is thus obtained the antidepressant dazadrol (5).
References
- Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.
- Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.
- Walter Lewis A, DE1905353A1 (1969 to Scherico Ltd).
- Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).
- Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).
Monoamine reuptake inhibitors | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |